---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-086616"
form_type: "8-K"
ticker: "PHAT"
cik: "0001783183"
company_name: "Phathom Pharmaceuticals, Inc."
filed_at: "2022-03-28T23:59:59+00:00"
generated_at: "2026-06-26T16:19:32.223950+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Phathom appoints Molly Henderson as CFO/Chief Business Officer; Guzzo to depart

## Summary
- Molly Henderson, former Urogen Pharma CFO, becomes Chief Financial and Business Officer effective April 5, 2022.
- Henderson's base salary $480,000; target bonus 45% of salary; receives options for 100k shares and 20k RSUs.
- Anthony Guzzo, Chief Accounting Officer and acting principal financial officer, to depart around Aug 15, 2022.
- Guzzo's departure not due to disagreement; vesting extended for certain PSVs and option exercise period to Dec 31, 2022.
- Henderson replaces Guzzo as principal financial and accounting officer effective April 5, 2022.

## SEC filing metadata
- accession: 0001193125-22-086616
- form_type: 8-K
- ticker: PHAT
- cik: 0001783183
- company_name: Phathom Pharmaceuticals, Inc.
- filed_at: 2022-03-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783183/000119312522086616/0001193125-22-086616-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783183/000119312522086616/d306197d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-086616
- JSON: https://secwatch.observer/filing/0001193125-22-086616.json
- Plain text: https://secwatch.observer/filing/0001193125-22-086616.txt

## Key facts
- Executive change
  Molly Henderson was appointed as Chief Financial and Business Officer at Phathom Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Chief Financial and Business Officer
  source text: On March 22, 2022, Phathom Pharmaceuticals, Inc. (the “Company”) announced the appointment of Molly Henderson, 51, as its Chief Financial and Business Officer effective April 5, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783183/000119312522086616/0001193125-22-086616-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.